Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Hereditary hemorrhagic telangiectasia (HHT) is associated with recurrent epistaxis in 90% of
cases. Good response to hormone treatment has been documented, although its use remains
controversial. A double-blind placebo-controlled trial with estrogen treatment did not show
any benefit over placebo. The aim of this study is to examine the efficacy of an
antiestrogenic agent, TAMOXIFEN, in the treatment of HHT-associated epistaxis. The study will
include up to 60 patients, over 18 years old.